Skip to main content

Table 3 Subset analyses of overall survival outcomes

From: Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies

OS from the time of initial brain metastasis in patients who: Median OS, (range), months
Were treated with anti-CTLA-4 antibody therapy
  Before the initial brain metastasis (n = 29) 10.5 (2.0–55.3)
  After the initial brain metastasis (n = 39) 19.2 (1.2–65.0)
Were treated with anti-PD-1 antibody therapy
  Before the initial brain metastasis (n = 1) 8.5
  After the initial brain metastasis (n = 28) 37.9 (5.3–65.0)
Were treated with BRAF and/or MEK inhibitor therapy
  Before the initial brain metastasis (n = 16) 10.9 (2.1–55.3)
  After the initial brain metastasis (n = 24) 12.7 (2.7–70.9)